Pegvaliase, PEGylated Anabaena variabilis phenylalanine ammonia lyase: molecular mechanisms & dependencies

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

Human evidence only

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

Pegvaliase supplies a PEGylated microbial phenylalanine ammonia lyase pathway that converts phenylalanine to trans-cinnamate and ammonia rather than tyrosine.
Pegvaliase, PEGylated Anabaena variabilis phenylalanine ammonia lyase → trans-Cinnamate source_derived_draftungraded
Experimental context and source evidence
evidence_access
Primary abstract
experimental_model
Enzyme mechanism described in the primary PRISM clinical report.
limitations
Lowering phenylalanine through this bypass does not restore the PAH-to-tyrosine reaction.
nutrient_topic
L-Phenylalanine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · L-Phenylalanine
plain_language
A drug can remove the accumulating substrate through a different chemical route.
primary_references
Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). · 2018 · https://pubmed.ncbi.nlm.nih.gov/29653686/ · DOI 10.1016/j.ymgme.2018.03.006
L-Phenylalanine: transport, protein synthesis, cofactor recycling and cross-nutrient mechanisms (2026-09-19) · lines 238–244
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Enzyme mechanism described in the primary PRISM clinical report. · source_derived_draft · unverified_draft
## l-phenylalanine-pal-bypass A drug can remove the accumulating substrate through a different chemical route. Pegvaliase supplies a PEGylated microbial phenylalanine ammonia lyase pathway that converts phenylalanine to trans-cinnamate and ammonia rather than tyrosine. Model: Enzyme mechanism described in the primary PRISM clinical report. Limitations: Lowering phenylalanine through this bypass does not restore the PAH-to-tyrosine reaction. Evidence access: Primary abstract Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). · 2018 · https://pubmed.ncbi.nlm.nih.gov/29653686/ · DOI 10.1016/j.ymgme.2018.03.006
Complete structured claim and evidence
PRISM studies in 261 adults with PAH deficiency found substantial phenylalanine reductions during induction, titration and maintenance pegvaliase treatment.
Pegvaliase, PEGylated Anabaena variabilis phenylalanine ammonia lyase → Human plasma phenylalanine concentration source_derived_draftungraded
Experimental context and source evidence
evidence_access
Primary abstract
experimental_model
Adult phase-3 clinical program with long-term titrated exposure.
limitations
Immune-mediated adverse events matter: 17 events in 12 participants met acute systemic hypersensitivity/anaphylaxis criteria. This is not dietary enzyme use.
nutrient_topic
L-Phenylalanine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · L-Phenylalanine
plain_language
The bypass can lower blood phenylalanine, but has its own treatment risks.
primary_references
Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). · 2018 · https://pubmed.ncbi.nlm.nih.gov/29653686/ · DOI 10.1016/j.ymgme.2018.03.006
L-Phenylalanine: transport, protein synthesis, cofactor recycling and cross-nutrient mechanisms (2026-09-19) · lines 246–252
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Adult phase-3 clinical program with long-term titrated exposure. · source_derived_draft · unverified_draft
## l-phenylalanine-pal-clinical The bypass can lower blood phenylalanine, but has its own treatment risks. PRISM studies in 261 adults with PAH deficiency found substantial phenylalanine reductions during induction, titration and maintenance pegvaliase treatment. Model: Adult phase-3 clinical program with long-term titrated exposure. Limitations: Immune-mediated adverse events matter: 17 events in 12 participants met acute systemic hypersensitivity/anaphylaxis criteria. This is not dietary enzyme use. Evidence access: Primary abstract Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). · 2018 · https://pubmed.ncbi.nlm.nih.gov/29653686/ · DOI 10.1016/j.ymgme.2018.03.006
Complete structured claim and evidence

The events it takes part in

A mechanism often involves more than two components. These are the full events, with every participant and its role.

Situations it appears in

Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

Open hypotheses

Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.

This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

Pegvaliase, PEGylated Anabaena variabilis phenylalanine ammonia lyase